ICPT Intercept Pharma

For the fiscal year ended 31/12/2022: Intercept Pharma's revenues decreased by 21.39% and amounted to 285.71M. Net income decreased by 91.26% to -174.86M. Net assets increased by 66.89% to -239.62M and EPS increased from -2.87 to 6.56.